“Biktarvy” Bictegravir /emtricitabine /tenofovir alafenamide
฿4,200.00 — available for auto-ship subscription
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a once-daily, single-tablet regimen used to treat HIV-1 infection. It combines three powerful antiretroviral agents to suppress viral replication and help individuals achieve and maintain an undetectable viral load. Biktarvy is known for its effectiveness, convenience, and minimal drug interactions, making it a preferred option for people starting or switching HIV treatment.
Indications
- Treatment of HIV-1 infection in adults and children weighing ≥14 kg.
- Suitable as an initial HIV treatment or for those switching from other antiretroviral regimens.
Benefits
- Effective Viral Suppression: Helps maintain undetectable viral loads (<50 copies/mL), preventing transmission (Undetectable = Untransmittable, U=U).
- Convenience & Adherence: Single daily pill reduces pill burden, improving adherence. Minimal Drug Interactions:
- Safe alongside most common medications without complex adjustments.
- Well-tolerated: Fewer side effects compared to older HIV regimens.
- Long-term safety: Lower risk of kidney problems and bone min
Biktarvy (Gilead Sciences) is currently the world’s best-selling HIV drug, favored for its, convenience, efficacy, safety profile, and price point.
